Trials / Sponsors / CatalYm GmbH
CatalYm GmbH
Industry · 6 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Visugromab in Cachexia International Trial Cancer-associated Cachexia | Phase 2 / Phase 3 | 2026-04-01 |
| Not Yet Recruiting | Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectab Unresectable or Metastatic Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Anti PD-(L)1 Compound, Child-Pugh A Hepatocellular Carcinoma | Phase 2 | 2026-02-01 |
| Recruiting | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Me Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | 2025-10-07 |
| Recruiting | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Met Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | 2025-08-01 |
| Active Not Recruiting | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder C Bladder Cancer, Adult Solid Tumor | Phase 2 | 2023-09-06 |
| Active Not Recruiting | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer Solid Tumor, Adult | Phase 1 / Phase 2 | 2020-12-09 |